期刊
VACCINES
卷 10, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/vaccines10050639
关键词
COVID-19; SARS-CoV-2; vaccines; anti-SARS-CoV-2 spike total antibodies; surrogate viral neutralizing antibody; T-cell immune response; CoronaVac; ChAdOx1; BNT162b2; booster
资金
- Rachadaphiseksomphot Fund of the Faculty of Medicine, Chulalongkorn University [RA(PO)002/64]
- King Chulalongkorn Memorial Hospital [HA-64-3300-21-024, EC-65-C7-030]
- National Research Council of Thailand [N35A640037, N35A640452]
- Thai Red Cross Fund
- Ratchadaphiseksomphot Matching Fund of the Faculty of Medicine, Chulalongkorn University
- Postdoctoral Fellowship Scholarships, Ratchadapisek Somphot Fund, Chulalongkorn University
- Biobank, Faculty of Medicine, Chulalongkorn University
- National Medical Research Council [STPRG-FY19-001, COVID19RF-003, OFLCG19May-0034]
- NIH/NIAID/CREID [07-049-7012-52338]
This study assessed the immune response against SARS-CoV-2 after receiving booster shots of BNT162b2 or ChAdOx1 among health care workers who previously received CoronaVac as their primary immunization. The study showed a significant increase in immune response after the booster, including against the Omicron variant. Immune responses decreased at 12 weeks after the booster but were still higher than post-primary vaccination.
Inactivated SARS-CoV-2 vaccine (CoronaVac) is commonly used in national immunization programs. However, the immune response significantly declines within a few months. Our study assessed the immune response against SARS-CoV-2 after receiving booster shots of BNT162b2 or ChAdOx1 among health care workers who previously received CoronaVac as their primary immunization. Fifty-six participants who received ChAdOx1 and forty-two participants who received BNT162b2 were enrolled into this study, which evaluated immune responses, including anti-SARS-CoV-2 spike total antibodies (Elecsys (R)), surrogated viral neutralization test (sVNT) to ancestral strain (cPass (TM); GenScript), five variants of concern (Alpha, Beta, Gamma, Delta, and Omicron) (Luminex; multiplex sVNT) and the ELISpot with spike (S1 and S2) peptide pool against the ancestral SARS-CoV-2 strain. The samples were analyzed at baseline, 4, and 12 weeks after primary immunization, as well as 4 and 12 weeks after receiving the booster. This study showed a significant increase in anti-SARS-CoV-2 spike total antibodies, sVNT, and T-cell immune response after the booster, including against the Omicron variant. Immune responses rapidly decreased in the booster group at 12 weeks after booster but were still higher than post-primary vaccination. A fourth dose or a second booster should be recommended, particularly in health care workers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据